Alexandra P. Wolanskyj-Spinner, M.D.

Open

• A Phase III, Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (VAYHIT1) (VAYHIT1) Rochester, Minn.

  The purpose of this study is to evaluate the effect of two different doses of ianalumab versus placebo in addition to first-line corticosteroids in maintaining platelet count ≥ 30 G/L in adult participants with primary ITP.